Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

LH vs EXAS vs DGX vs NTRA vs ILMN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LH
Labcorp Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$21.24B
5Y Perf.+71.3%
EXAS
Exact Sciences Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$20.02B
5Y Perf.+20.4%
DGX
Quest Diagnostics Incorporated

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$21.12B
5Y Perf.+61.3%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$31.16B
5Y Perf.+401.3%
ILMN
Illumina, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$21.07B
5Y Perf.-60.7%

LH vs EXAS vs DGX vs NTRA vs ILMN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LH logoLH
EXAS logoEXAS
DGX logoDGX
NTRA logoNTRA
ILMN logoILMN
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$21.24B$20.02B$21.12B$31.16B$21.07B
Revenue (TTM)$14.14B$3.25B$11.28B$2.31B$4.39B
Net Income (TTM)$942M$-208M$1.02B$-208M$853M
Gross Margin27.8%69.7%33.2%64.8%67.1%
Operating Margin11.0%-6.4%14.3%-13.4%20.9%
Forward P/E14.5x582.8x17.8x26.8x
Total Debt$7.20B$2.52B$6.92B$214M$2.55B
Cash & Equiv.$532M$956M$420M$1.08B$1.42B

LH vs EXAS vs DGX vs NTRA vs ILMNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LH
EXAS
DGX
NTRA
ILMN
StockMay 20May 26Return
Labcorp Holdings In… (LH)100171.3+71.3%
Exact Sciences Corp… (EXAS)100120.4+20.4%
Quest Diagnostics I… (DGX)100161.3+61.3%
Natera, Inc. (NTRA)100501.3+401.3%
Illumina, Inc. (ILMN)10039.3-60.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: LH vs EXAS vs DGX vs NTRA vs ILMN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DGX and ILMN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Illumina, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. LH, EXAS, and NTRA also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
LH
Labcorp Holdings Inc.
The Value Play

LH ranks third and is worth considering specifically for value.

  • Lower P/E (14.5x vs 26.8x)
Best for: value
EXAS
Exact Sciences Corporation
The Growth Play

EXAS is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 17.7%, EPS growth 80.3%, 3Y rev CAGR 15.9%
  • Lower volatility, beta 0.12, current ratio 2.43x
  • +96.9% vs LH's +6.1%
Best for: growth exposure and sleep-well-at-night
DGX
Quest Diagnostics Incorporated
The Income Pick

DGX has the current edge in this matchup, primarily because of its strength in income & stability and defensive.

  • Dividend streak 15 yrs, beta 0.07, yield 1.6%
  • Beta 0.07, yield 1.6%, current ratio 1.04x
  • Beta 0.07 vs NTRA's 1.26
  • 1.6% yield, 15-year raise streak, vs LH's 1.1%, (3 stocks pay no dividend)
Best for: income & stability and defensive
NTRA
Natera, Inc.
The Long-Run Compounder

NTRA is the clearest fit if your priority is long-term compounding.

  • 20.9% 10Y total return vs DGX's 181.3%
  • 35.9% revenue growth vs ILMN's -0.8%
Best for: long-term compounding
ILMN
Illumina, Inc.
The Quality Compounder

ILMN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 19.4% margin vs NTRA's -9.0%
  • 13.4% ROA vs NTRA's -10.6%, ROIC 16.8% vs -36.1%
Best for: quality and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthNTRA logoNTRA35.9% revenue growth vs ILMN's -0.8%
ValueLH logoLHLower P/E (14.5x vs 26.8x)
Quality / MarginsILMN logoILMN19.4% margin vs NTRA's -9.0%
Stability / SafetyDGX logoDGXBeta 0.07 vs NTRA's 1.26
DividendsDGX logoDGX1.6% yield, 15-year raise streak, vs LH's 1.1%, (3 stocks pay no dividend)
Momentum (1Y)EXAS logoEXAS+96.9% vs LH's +6.1%
Efficiency (ROA)ILMN logoILMN13.4% ROA vs NTRA's -10.6%, ROIC 16.8% vs -36.1%

LH vs EXAS vs DGX vs NTRA vs ILMN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LHLabcorp Holdings Inc.
FY 2025
LabCorp Diagnostics
100.0%$10.9B
EXASExact Sciences Corporation
FY 2025
Screening
77.9%$2.5B
Precision Oncology
22.1%$717M
DGXQuest Diagnostics Incorporated
FY 2025
Diagnostic Information Services Business
100.0%$10.8B
NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M
ILMNIllumina, Inc.
FY 2025
Sequencing
91.8%$4.0B
Microarray
8.2%$358M

LH vs EXAS vs DGX vs NTRA vs ILMN — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLILMNLAGGINGEXAS

Income & Cash Flow (Last 12 Months)

ILMN leads this category, winning 3 of 6 comparable metrics.

LH is the larger business by revenue, generating $14.1B annually — 6.1x NTRA's $2.3B. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to NTRA's -9.0%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
RevenueTrailing 12 months$14.1B$3.2B$11.3B$2.3B$4.4B
EBITDAEarnings before interest/tax$2.2B-$41M$1.9B-$310M$1.1B
Net IncomeAfter-tax profit$942M-$208M$1.0B-$208M$853M
Free Cash FlowCash after capex$1.4B$357M$1.3B$97M$989M
Gross MarginGross profit ÷ Revenue+27.8%+69.7%+33.2%+64.8%+67.1%
Operating MarginEBIT ÷ Revenue+11.0%-6.4%+14.3%-13.4%+20.9%
Net MarginNet income ÷ Revenue+6.7%-6.4%+9.1%-9.0%+19.4%
FCF MarginFCF ÷ Revenue+9.8%+11.0%+11.8%+4.2%+22.5%
Rev. Growth (YoY)Latest quarter vs prior year+5.8%+23.1%+9.2%+39.8%+4.8%
EPS Growth (YoY)Latest quarter vs prior year+32.9%+90.4%+15.5%+185.4%+6.1%
ILMN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

LH leads this category, winning 4 of 6 comparable metrics.

At 21.8x trailing earnings, DGX trades at a 14% valuation discount to ILMN's 25.5x P/E. On an enterprise value basis, LH's 12.7x EV/EBITDA is more attractive than ILMN's 19.6x.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
Market CapShares × price$21.2B$20.0B$21.1B$31.2B$21.1B
Enterprise ValueMkt cap + debt − cash$27.9B$21.6B$27.6B$30.3B$22.2B
Trailing P/EPrice ÷ TTM EPS24.67x-95.37x21.81x-144.62x25.45x
Forward P/EPrice ÷ next-FY EPS est.14.45x582.83x17.77x26.77x
PEG RatioP/E ÷ EPS growth rate6.01x
EV / EBITDAEnterprise value multiple12.70x12.71x19.58x
Price / SalesMarket cap ÷ Revenue1.52x6.16x1.91x13.51x4.86x
Price / BookPrice ÷ Book value/share2.50x8.24x2.96x17.55x7.95x
Price / FCFMarket cap ÷ FCF17.61x56.10x15.54x285.53x22.63x
LH leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

ILMN leads this category, winning 6 of 9 comparable metrics.

ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-15 for NTRA. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs NTRA's 5/9, reflecting strong financial health.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
ROE (TTM)Return on equity+10.9%-8.7%+13.8%-15.3%+32.8%
ROA (TTM)Return on assets+5.1%-3.5%+6.3%-10.6%+13.4%
ROICReturn on invested capital+7.8%-3.6%+8.8%-36.1%+16.8%
ROCEReturn on capital employed+9.9%-4.0%+11.5%-18.3%+17.6%
Piotroski ScoreFundamental quality 0–977758
Debt / EquityFinancial leverage0.83x1.05x0.95x0.13x0.94x
Net DebtTotal debt minus cash$6.7B$1.6B$6.5B-$862M$1.1B
Cash & Equiv.Liquid assets$532M$956M$420M$1.1B$1.4B
Total DebtShort + long-term debt$7.2B$2.5B$6.9B$214M$2.6B
Interest CoverageEBIT ÷ Interest expense6.22x-5.47x6.26x-25.21x12.09x
ILMN leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $3,717 for ILMN. Over the past 12 months, EXAS leads with a +96.9% total return vs LH's +6.1%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs ILMN's -10.0% — a key indicator of consistent wealth creation.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
YTD ReturnYear-to-date+2.8%+3.1%+10.8%-3.9%+3.2%
1-Year ReturnPast 12 months+6.1%+96.9%+9.9%+37.3%+81.7%
3-Year ReturnCumulative with dividends+39.4%+53.0%+48.5%+314.0%-27.1%
5-Year ReturnCumulative with dividends+12.6%+0.4%+47.7%+115.9%-62.8%
10-Year ReturnCumulative with dividends+150.7%+1669.1%+181.3%+2089.4%+0.7%
CAGR (3Y)Annualised 3-year return+11.7%+15.2%+14.1%+60.6%-10.0%
NTRA leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — EXAS and DGX each lead in 1 of 2 comparable metrics.

DGX is the less volatile stock with a 0.07 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs NTRA's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
Beta (5Y)Sensitivity to S&P 5000.52x0.12x0.07x1.26x1.23x
52-Week HighHighest price in past year$293.72$104.98$213.50$256.36$155.53
52-Week LowLowest price in past year$239.67$38.81$164.65$131.81$73.86
% of 52W HighCurrent price vs 52-week peak+87.9%+99.9%+89.4%+85.7%+89.2%
RSI (14)Momentum oscillator 0–10040.376.440.157.165.2
Avg Volume (50D)Average daily shares traded579K4.2M841K1.3M1.5M
Evenly matched — EXAS and DGX each lead in 1 of 2 comparable metrics.

Analyst Outlook

DGX leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: LH as "Buy", EXAS as "Buy", DGX as "Hold", NTRA as "Buy", ILMN as "Buy". Consensus price targets imply 20.7% upside for LH (target: $311) vs -1.6% for EXAS (target: $103). For income investors, DGX offers the higher dividend yield at 1.64% vs LH's 1.11%.

MetricLH logoLHLabcorp Holdings …EXAS logoEXASExact Sciences Co…DGX logoDGXQuest Diagnostics…NTRA logoNTRANatera, Inc.ILMN logoILMNIllumina, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuyBuy
Price TargetConsensus 12-month target$311.33$103.18$220.57$262.50$147.38
# AnalystsCovering analysts3541342750
Dividend YieldAnnual dividend ÷ price+1.1%+1.6%
Dividend StreakConsecutive years of raises015
Dividend / ShareAnnual DPS$2.87$3.12
Buyback YieldShare repurchases ÷ mkt cap+2.1%+0.1%+2.1%0.0%+3.5%
DGX leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ILMN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LH leads in 1 (Valuation Metrics). 1 tied.

Best OverallIllumina, Inc. (ILMN)Leads 2 of 6 categories
Loading custom metrics...

LH vs EXAS vs DGX vs NTRA vs ILMN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is LH or EXAS or DGX or NTRA or ILMN a better buy right now?

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Labcorp Holdings Inc. (LH) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LH or EXAS or DGX or NTRA or ILMN?

On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 21.

8x versus Illumina, Inc. at 25. 5x. On forward P/E, Labcorp Holdings Inc. is actually cheaper at 14. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — LH or EXAS or DGX or NTRA or ILMN?

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -62. 8% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus ILMN's +0. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LH or EXAS or DGX or NTRA or ILMN?

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 1613% more volatile than DGX relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — LH or EXAS or DGX or NTRA or ILMN?

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LH or EXAS or DGX or NTRA or ILMN?

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LH or EXAS or DGX or NTRA or ILMN more undervalued right now?

On forward earnings alone, Labcorp Holdings Inc.

(LH) trades at 14. 5x forward P/E versus 582. 8x for Exact Sciences Corporation — 568. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LH: 20. 7% to $311. 33.

08

Which pays a better dividend — LH or EXAS or DGX or NTRA or ILMN?

In this comparison, DGX (1.

6% yield), LH (1. 1% yield) pay a dividend. EXAS, NTRA, ILMN do not pay a meaningful dividend and should not be held primarily for income.

09

Is LH or EXAS or DGX or NTRA or ILMN better for a retirement portfolio?

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LH and EXAS and DGX and NTRA and ILMN?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LH is a mid-cap quality compounder stock; EXAS is a mid-cap high-growth stock; DGX is a mid-cap quality compounder stock; NTRA is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock. LH, DGX pay a dividend while EXAS, NTRA, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

LH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

EXAS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 41%
Run This Screen
Stocks Like

DGX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

NTRA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 38%
Run This Screen
Stocks Like

ILMN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LH and EXAS and DGX and NTRA and ILMN on the metrics below

Revenue Growth>
%
(LH: 5.8% · EXAS: 23.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.